Stock 0GY1 SWEDISH ORPHAN BIOVITRUM
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

SWEDISH ORPHAN BIOVITRUM Stock London S.E.

Equities

0GY1

Pharmaceuticals

End-of-day quote London S.E.
Other stock markets
- SEK - Intraday chart for SWEDISH ORPHAN BIOVITRUM
07-02 Sweden's Sobi Begins Rolling Application for Gout Treatment in US MT
07-02 Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout CI

Financials

Sales 2024 * 24.62B 2.35B 3.21B Sales 2025 * 27.29B 2.61B 3.56B Capitalization 94.01B 8.98B 12.25B
Net income 2024 * 3.44B 329M 448M Net income 2025 * 4.97B 475M 648M EV / Sales 2024 * 4.4 x
Net Debt 2024 * 14.44B 1.38B 1.88B Net Debt 2025 * 8.83B 843M 1.15B EV / Sales 2025 * 3.77 x
P/E ratio 2024 *
26.9 x
P/E ratio 2025 *
18.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 50.9%
More Fundamentals * Assessed data

Latest news about SWEDISH ORPHAN BIOVITRUM

Sweden's Sobi Begins Rolling Application for Gout Treatment in US MT
Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout CI
Sobi Wins EU Approval for Hemophilia A Drug Altuvoct MT
European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A CI
BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB CI
Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment DJ
Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member CI
Sobi Finalizes Inaugural SEK3 Billion Bond Issue MT
Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy MT
Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug MT
Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A CI
Sobi's SEK10 Billion Note Program Gets Regulatory Nod in Sweden MT
Transcript : Swedish Orphan Biovitrum AB, Q1 2024 Earnings Call, Apr 25, 2024
Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Swedish Orphan Biovitrum AB Provides Earnings Guidance for 2024 CI
More news

Latest transcript on SWEDISH ORPHAN BIOVITRUM

Logo SWEDISH ORPHAN BIOVITRUM
Swedish Orphan Biovitrum AB, Q1 2024 Earnings Call, Apr 25, 2024
More transcripts

Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM

Swedish Orphan Biovitrum : Sobi publishes its Report for the Second Quarter 2015 - raises guidance GL
More recommendations

Press releases SWEDISH ORPHAN BIOVITRUM

Invitation: Sobi's Q2 2024 report PU
Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout AQ
Swedish Orphan Biovitrum : European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A PU
Swedish Orphan Biovitrum : Sobi to present new haemophilia data at ISTH 2024 PU
Swedish Orphan Biovitrum : Sobi to present new data across its haematology portfolio at the 2024 EHA congress PU
More press releases

News in other languages on SWEDISH ORPHAN BIOVITRUM

Avis d'analystes du jour : Hermès, Sanofi, STMicroelectronics, BNP Paribas, Pluxee, Valeo, Nestlé...
AVIS D'ANALYSTES DU JOUR : Air Liquide, Carrefour, STMicro, Sartorius Stedim Biotech, Schneider, Soitec...
OPINIONES DE LOS ANALISTAS DEL DÍA : Inditex, Acciona Energia, Merlin Properties, Tod's, Euronext, ...
Ericsson : nouveau directeur financier début avril
C'est pas bientaux fini ?
More news

Managers and Directors - SWEDISH ORPHAN BIOVITRUM

Managers TitleAgeSince
Guido Oelkers CEO
 Chief Executive Officer 59 17-05-21
Henrik Stenqvist DFI
 Director of Finance/CFO 57 18-07-19
Lydia Abad-Franch CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Sven Anders Ullman BRD
 Director/Board Member 68 20-12-31
Annette Clancy CHM
 Chairman 70 14-05-07
Staffan Schüberg BRD
 Director/Board Member 55 19-12-31
More insiders

Company Profile

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Sector
Pharmaceuticals
Calendar
2024-07-15 - Q2 2024 Earnings Release
Related indices
STOXX EUROPE 600 (EUR)
More about the company

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+4.57% 97.7B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+5.66% 41.43B
BIOGEN INC. Stock Biogen Inc.
-12.80% 32.85B
UCB Stock UCB
+80.99% 29.33B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.53% 15.47B
INCYTE CORPORATION Stock Incyte Corporation
-8.70% 12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.22% 11.51B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+183.25% 10.74B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-55.41% 8.97B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. 0GY1 Stock